Transgene Stock Forecast for 2023 - 2025 - 2030
Updated on 05/04/2024
Transgene Stock Forecast and Price Target
Transgene's stock is projected to advance by 182.26% from the previous closing price if it reaches the average target of 3.50€ by the year's end, as reputable analysts recently projected. This potential upside is calculated on a high-end estimate of 3.50€ and a low-end estimate of 3.50€. If you want to buy TNG stock, it might be a good idea to look at its competitors too.
182.26% Upside
Transgene Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Transgene's Price has grown, increasing from 0.00€ to 0.00€ – an increase of 100.00%. For next year, the 1 analysts predict Fair Value of 1.32€, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is Fair Valueof 2.25€, which would mean a seven-year growth forecast of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VIRP Stock Forecast | Virbac | Outperform |
18
|
355.50€ | Buy/Sell | 348.34€ | 3.80% |
| ABVX Stock Forecast | ABIVAX Société Anonyme | Buy |
6
|
14.06€ | Buy/Sell | 24.80€ | 166.71% |
| VLA Stock Forecast | Valneva | Outperform |
12
|
3.43€ | Buy/Sell | 9.32€ | 166.76% |
| NANO Stock Forecast | Nanobiotix | Buy |
6
|
5.88€ | Buy/Sell | 11.13€ | 81.97% |
| IVA Stock Forecast | Inventiva | Buy |
11
|
3.16€ | Buy/Sell | 17.52€ | 327.22% |
Transgene Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Transgene's Revenue has grown, increasing from 9.34€M to 10.23€M – an increase of 9.53%. For next year, the 1 analysts predict Revenue of 39.80€M, which would mean an increase of 289.05%. Over the next seven years, the pros' prediction is Revenueof 42.90€M, which would mean a seven-year growth forecast of 319.37%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IPH Stock Forecast | Innate Pharma | Outperform |
10
|
2.21€ | Buy/Sell | 6.32€ | 216.74% |
| ALCLS Stock Forecast | Cellectis | - |
10
|
2.76€ | Buy/Sell | 10.60€ | -100.00% |
| GNFT Stock Forecast | Genfit | Buy |
10
|
3.24€ | Buy/Sell | 9.26€ | 177.78% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALERS Stock Forecast | Eurobio Scientific Société a... | Buy |
16
|
14.50€ | Buy/Sell | 27.00€ | 106.90% |
| ADOC Stock Forecast | Adocia | Hold |
7
|
8.47€ | Buy/Sell | 9.70€ | 14.52% |
| DBV Stock Forecast | DBV Technologies | Outperform |
5
|
1.20€ | Buy/Sell | 4.07€ | 233.33% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| OSE Stock Forecast | OSE Immunotherapeutics | Buy |
7
|
6.20€ | Buy/Sell | 7.15€ | 15.32% |
| ALONC Stock Forecast | Oncodesign Société Anonyme | - |
12
|
14.42€ | Buy/Sell | 17.43€ | -100.00% |
| ENXTPA:GKTX Stock Forecast | Genkyotex | - |
-15
|
3.20€ | Buy/Sell | 5.40€ | -100.00% |
Transgene EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Transgene's EBITDA has grown by 26.02%, from -22.48€M to -28.33€M. In the following year, 1 experts forecast that Transgene's EBITDA will decrease by 58.70%, to -11.70€M. Over the next seven years, experts predict that EBITDA will grow by 26.58%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABNX Stock Forecast | ABIONYX Pharma | Buy |
4
|
1.07€ | Buy/Sell | 10.50€ | 881.31% |
| SIGHT Stock Forecast | GenSight Biologics | Underperform |
9
|
0.40€ | Buy/Sell | 1.45€ | 0.00% |
| ALVIO Stock Forecast | Valerio Therapeutics Société... | - |
8
|
0.13€ | Buy/Sell | 1.30€ | 15.38% |
Transgene EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Transgene's EBIT has grown from -24.19€M to -30.01€M – a 24.06% increase. 1 analysts predict Transgene's EBIT will decrease by 47.68% in the next year, reaching -15.70€M. Over the next seven years, the forecast is for EBIT to grow by 25.32%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| POXEL Stock Forecast | Poxel | - |
9
|
0.65€ | Buy/Sell | 3.50€ | -100.00% |
| PHXM Stock Forecast | PHAXIAM Therapeutics | Buy |
4
|
2.88€ | Buy/Sell | 9.85€ | 137.85% |
| LYS Stock Forecast | Lysogene | - |
0
|
1.70€ | Buy/Sell | 0.00€ | -100.00% |
Transgene EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Transgene's EPS has grown, increasing from -0.21€ to 0.00€ – an increase of 100.00%. For next year, the 1 analysts predict EPS of -0.14€, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is EPSof -0.36€, which would mean a seven-year growth forecast of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALHYG Stock Forecast | Hybrigenics | - |
0
|
0.01€ | Buy/Sell | 0.00€ | -100.00% |
| ALBPS Stock Forecast | Biophytis | - |
0
|
0.00€ | Buy/Sell | 10.00€ | 0.00% |
| ALQGC Stock Forecast | Quantum Genomics Société Ano... | Sell |
5
|
0.12€ | Buy/Sell | 0.10€ | -16.67% |
.jpg)